Next Article in Journal
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
Next Article in Special Issue
Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
Previous Article in Journal
Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group
Previous Article in Special Issue
Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
 
 
Review

Article Versions Notes

Cancers 2022, 14(5), 1129; https://doi.org/10.3390/cancers14051129
Action Date Notes Link
article xml file uploaded 23 February 2022 07:38 CET Original file -
article xml uploaded. 23 February 2022 07:38 CET Update https://www.mdpi.com/2072-6694/14/5/1129/xml
article pdf uploaded. 23 February 2022 07:38 CET Version of Record https://www.mdpi.com/2072-6694/14/5/1129/pdf
article html file updated 23 February 2022 07:39 CET Original file -
article html file updated 1 August 2022 02:10 CEST Update https://www.mdpi.com/2072-6694/14/5/1129/html
Back to TopTop